



**Biocon Limited**  
20th KM, Hosur Road  
Electronic City  
Bangalore 560 100, India  
T 91 80 2808 2808  
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

November 21, 2020

To The Manager <b>BSE Limited</b> Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 <b>Scrip Code – 532523</b>	To The Manager, <b>National Stock Exchange of India Limited</b> Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 <b>Scrip Symbol - Biocon</b>
---	---

**Subject: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 (“SEBI Listing Regulation”)**

Dear Sir/Madam,

In compliance with Regulation 23(9) of SEBI Listing Regulations, please find enclosed disclosure of related party transactions on consolidated basis for the half year ended September 30, 2020, drawn in accordance with applicable accounting standard.

The above information will also be available on the website of the company at [www.biocon.com](http://www.biocon.com).

Kindly take on record the above information and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

*Mayank Verma*



**Mayank Verma**  
**Company Secretary and Compliance Officer**

**Disclosure of related party transactions- On consolidated basis  
In pursuance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulation, 2018  
(All amounts are in Indian Rupees Million)**

**List of related parties with whom the Group had transactions during the period:**

<b>Name of related parties</b>	<b>Nature of relationship</b>
<b>Key management personnel</b>	
Kiran Mazumdar-Shaw	Executive Chairperson
Siddharth Mittal	Managing Director & CEO
Anupam Jindal	Chief Financial Officer (w.e.f September 22, 2020)
Indranil Sen	Chief Financial Officer (Interim) (w.e.f May 15, 2020 - upto September 22, 2020)
Mayank Verma	Company Secretary
Daniel M Bradbury	Independent director
Mary Harney	Independent director
Vijay K Kuchroo	Independent director
M Damodaran	Independent director
Bobby K Parikh	Independent director
John Shaw	Non-executive director
Ravi Mazumdar	Non-executive director
<b>Joint Ventures</b>	
NeoBiocon FZ LLC	Joint-venture
<b>Other related parties</b>	
Biocon Foundation	Trust in which key management personnel are the Board of Trustees
Immuneel Therapeutics Private Limited	Enterprise in which a director of the Company is a shareholder
Mazumdar Shaw Medical Foundation	Trust in which key management personnel are the Board of Trustees
Glentec International Limited	Enterprise owned by key management personnel
Catherine Rosenberg	Relative of a director
Clarie Mazumdar	Relative of a director
Jeeves	Enterprise in which relative to a director of the Company is proprietor
Narayana Hrudayalaya Limited	Enterprise in which a director of the Company is a member of board of directors

**The Group has the following related party transactions**

<b>Particulars</b>	<b>Transactions / Balances</b>	<b>Half year ended September 30, 2020</b>
<b>Key management personnel</b>	Salary and perquisites [refer note (a) & (b) below]	55
	Sitting fees and commission	17
	Outstanding as at the period end:	
	- Trade and other payables	4
<b>Joint Venture</b>	Purchase of goods	258
	Sales promotion expenses	17
	Expenses incurred on behalf of the related party	*
	Outstanding as at the period end:	
	- Trade and other receivables	5
	- Trade and other payables	595
<b>Other related parties</b>	Sale of goods	22
	Sale of services	1
	Salary and perquisites (includes sitting fees)	24
	Health services availed	1
	CSR Expenditure	14
	Other expenses	21
	Outstanding as at the period end:	
	- Trade and other receivables	21
	- Trade and other payables	16

\* Amounts are not represented since the amounts are rounded off to Rupees million.

(a) The remuneration to key managerial personnel does not include the provisions made for gratuity and compensated absences, as they are obtained on an actuarial basis for the Company as a whole.

(b) Share-based compensation expense allocable to key management personnel is Rs 37 which is not included in the remuneration disclosed above.

(c) The above disclosures include related parties as per Ind AS 24 on "Related Party Disclosures" and Companies Act, 2013.

(d) All transactions with these related parties are priced on an arms length basis and none of the balances are secured.